• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从骨肉瘤早期起始事件到转移和疾病进展的晚期事件,了解骨肉瘤的生物学特性。

Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression.

作者信息

Zhu Limin, McManus Madonna M, Hughes Dennis P M

机构信息

Department of Pediatrics - Research, UT MD Anderson Cancer Center , Houston, TX , USA.

出版信息

Front Oncol. 2013 Sep 17;3:230. doi: 10.3389/fonc.2013.00230.

DOI:10.3389/fonc.2013.00230
PMID:24062983
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3775316/
Abstract

The two most common primary bone malignancies, osteosarcoma (OS), and Ewing sarcoma (ES), are both aggressive, highly metastatic cancers that most often strike teens, though both can be found in younger children and adults. Despite distinct origins and pathogenesis, both diseases share several mechanisms of progression and metastasis, including neovascularization, invasion, anoikis resistance, chemoresistance, and evasion of the immune response. Some of these processes are well-studies in more common carcinoma models, and the observation from adult diseases may be readily applied to pediatric bone sarcomas. Neovascularization, which includes angiogenesis and vasculogenesis, is a clear example of a process that is likely to be similar between carcinomas and sarcomas, since the responding cells are the same in each case. Chemoresistance mechanisms also may be similar between other cancers and the bone sarcomas. Since OS and ES are mesenchymal in origin, the process of epithelial-to-mesenchymal transition is largely absent in bone sarcomas, necessitating different approaches to study progression and metastasis in these diseases. One process that is less well-studied in bone sarcomas is dormancy, which allows micrometastatic disease to remain viable but not growing in distant sites - typically the lungs - for months or years before renewing growth to become overt metastatic disease. By understanding the basic biology of these processes, novel therapeutic strategies may be developed that could improve survival in children with OS or ES.

摘要

两种最常见的原发性骨恶性肿瘤,骨肉瘤(OS)和尤因肉瘤(ES),都是侵袭性强、具有高度转移性的癌症,最常发生于青少年,不过在幼儿和成人中也可发现。尽管起源和发病机制不同,但这两种疾病在进展和转移方面有几种共同机制,包括新血管生成、侵袭、失巢凋亡抗性、化疗耐药性以及逃避免疫反应。其中一些过程在更常见的癌模型中有深入研究,从成人疾病中观察到的情况可能很容易应用于儿童骨肉瘤。新血管生成,包括血管生成和血管发生,显然是一个在癌和肉瘤之间可能相似的过程,因为每种情况下的反应细胞是相同的。其他癌症和骨肉瘤之间的化疗耐药机制也可能相似。由于骨肉瘤起源于间充质,上皮-间充质转化过程在骨肉瘤中基本不存在,因此需要采用不同方法来研究这些疾病的进展和转移。在骨肉瘤中研究较少的一个过程是休眠,它使微转移病灶在数月或数年内在远处部位(通常是肺部)保持存活但不生长,然后重新生长成为明显的转移性疾病。通过了解这些过程的基本生物学特性,可能会开发出新的治疗策略,从而提高骨肉瘤或尤因肉瘤患儿的生存率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2216/3775316/ade76eb5d967/fonc-03-00230-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2216/3775316/2b04407c2dae/fonc-03-00230-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2216/3775316/f3e4644dbb02/fonc-03-00230-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2216/3775316/fc5bbe353b48/fonc-03-00230-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2216/3775316/ade76eb5d967/fonc-03-00230-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2216/3775316/2b04407c2dae/fonc-03-00230-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2216/3775316/f3e4644dbb02/fonc-03-00230-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2216/3775316/fc5bbe353b48/fonc-03-00230-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2216/3775316/ade76eb5d967/fonc-03-00230-g004.jpg

相似文献

1
Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression.从骨肉瘤早期起始事件到转移和疾病进展的晚期事件,了解骨肉瘤的生物学特性。
Front Oncol. 2013 Sep 17;3:230. doi: 10.3389/fonc.2013.00230.
2
Pediatric sarcomas display a variable EpCAM expression in a histology-dependent manner.小儿肉瘤以组织学依赖的方式表现出可变的上皮细胞黏附分子(EpCAM)表达。
Transl Oncol. 2020 Nov;13(11):100846. doi: 10.1016/j.tranon.2020.100846. Epub 2020 Aug 14.
3
Sarcoma Stem Cell Heterogeneity.肉瘤干细胞异质性。
Adv Exp Med Biol. 2019;1123:95-118. doi: 10.1007/978-3-030-11096-3_7.
4
Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: tumor models for cancer drug discovery.骨肉瘤和尤文肉瘤的异种移植和基因工程小鼠模型系统:癌症药物发现的肿瘤模型。
Expert Opin Drug Discov. 2013 Oct;8(10):1181-9. doi: 10.1517/17460441.2013.817988. Epub 2013 Jul 12.
5
Homogenous and Heterogenous Prognostic Factors for Patients with Bone Sarcoma.骨肉瘤患者的同质和异质预后因素。
Orthop Surg. 2021 Feb;13(1):134-144. doi: 10.1111/os.12851. Epub 2020 Dec 10.
6
Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.阿帕替尼作为晚期骨与软组织肉瘤的靶向治疗:在逆转多药耐药的同时又产生耐药性的困境。
Angiogenesis. 2020 Aug;23(3):279-298. doi: 10.1007/s10456-020-09716-y. Epub 2020 Apr 24.
7
Understanding micrometastatic disease and Anoikis resistance in ewing family of tumors and osteosarcoma.了解尤文家族肿瘤和骨肉瘤中的微转移疾病和失巢凋亡抵抗。
Oncologist. 2010;15(6):627-35. doi: 10.1634/theoncologist.2010-0093. Epub 2010 May 17.
8
New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?原发性骨肿瘤及其微环境中 Wnt/β-连环蛋白信号通路的新见解:开发治疗策略的有前途靶点?
Int J Mol Sci. 2019 Jul 31;20(15):3751. doi: 10.3390/ijms20153751.
9
Modeling the Tumor Microenvironment and Pathogenic Signaling in Bone Sarcoma.骨肉瘤肿瘤微环境与致病信号建模。
Tissue Eng Part B Rev. 2020 Jun;26(3):249-271. doi: 10.1089/ten.teb.2019.0302. Epub 2020 Feb 14.
10
Exosomes in Bone Sarcomas: Key Players in Metastasis.骨肉瘤中的外泌体:转移的关键参与者。
Cells. 2020 Jan 17;9(1):241. doi: 10.3390/cells9010241.

引用本文的文献

1
Exploring bone-tumor interactions through 3D models: Implications for primary and metastatic cancers.通过三维模型探索骨肿瘤相互作用:对原发性和转移性癌症的启示
J Bone Oncol. 2025 Jun 17;53:100698. doi: 10.1016/j.jbo.2025.100698. eCollection 2025 Aug.
2
Knockdown as a Therapeutic Strategy in Osteosarcoma: Effects on Proliferation and Drug Response in U2OS and HOS Cells.基因敲低作为骨肉瘤的一种治疗策略:对U2OS和HOS细胞增殖及药物反应的影响
Int J Mol Sci. 2025 Feb 18;26(4):1736. doi: 10.3390/ijms26041736.
3
Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.

本文引用的文献

1
ERBB4 confers metastatic capacity in Ewing sarcoma.ERBB4 赋予尤文肉瘤转移能力。
EMBO Mol Med. 2013 Jul;5(7):1087-102. doi: 10.1002/emmm.201202343. Epub 2013 May 16.
2
miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor.miR-125b 促进尤文肉瘤/原始神经外胚层肿瘤的化疗耐药性。
Cancer Cell Int. 2013 Mar 4;13(1):21. doi: 10.1186/1475-2867-13-21.
3
DKK2 mediates osteolysis, invasiveness, and metastatic spread in Ewing sarcoma.DKK2 介导尤因肉瘤中的溶骨作用、侵袭和转移扩散。
过继性自然杀伤细胞疗法在儿科骨肿瘤未满足的治疗需求方面的前景与进展。
Int J Mol Sci. 2023 May 5;24(9):8324. doi: 10.3390/ijms24098324.
4
Molecular Subtyping and Survival Analysis of Osteosarcoma Reveals Prognostic Biomarkers and Key Canonical Pathways.骨肉瘤的分子分型与生存分析揭示预后生物标志物和关键经典通路
Cancers (Basel). 2023 Apr 4;15(7):2134. doi: 10.3390/cancers15072134.
5
Incidence of primary bone sarcomas in Iranian population (2008-2015): A national population-based study.伊朗人群中原发性骨肉瘤的发病率(2008 - 2015年):一项基于全国人口的研究。
Caspian J Intern Med. 2022 Fall;13(4):741-748. doi: 10.22088/cjim.13.4.741.
6
Ewing sarcoma with very late metastasis in the skull: a case report.颅骨中非常晚期转移的尤因肉瘤:病例报告。
J Med Case Rep. 2022 Nov 15;16(1):419. doi: 10.1186/s13256-022-03656-5.
7
Descriptive epidemiology of soft tissue and bone sarcomas in Lebanon.黎巴嫩软组织和骨肉瘤的描述性流行病学。
J Int Med Res. 2022 Mar;50(3):3000605221082852. doi: 10.1177/03000605221082852.
8
DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcoma.基于 DNA 甲基化的分类器和基因表达特征可检测骨肉瘤中的 BRCA 样特征。
PLoS Comput Biol. 2021 Nov 11;17(11):e1009562. doi: 10.1371/journal.pcbi.1009562. eCollection 2021 Nov.
9
Exosomes as Efficient Nanocarriers in Osteosarcoma: Biological Functions and Potential Clinical Applications.外泌体作为骨肉瘤中高效的纳米载体:生物学功能及潜在临床应用
Front Cell Dev Biol. 2021 Oct 12;9:737314. doi: 10.3389/fcell.2021.737314. eCollection 2021.
10
Single-Cell Transcriptomics Reveals the Complexity of the Tumor Microenvironment of Treatment-Naive Osteosarcoma.单细胞转录组学揭示了未经治疗的骨肉瘤肿瘤微环境的复杂性。
Front Oncol. 2021 Jul 21;11:709210. doi: 10.3389/fonc.2021.709210. eCollection 2021.
Cancer Res. 2013 Jan 15;73(2):967-77. doi: 10.1158/0008-5472.CAN-12-1492. Epub 2012 Nov 30.
4
microRNA-195 suppresses osteosarcoma cell invasion and migration in vitro by targeting FASN.微小RNA-195通过靶向脂肪酸合酶抑制骨肉瘤细胞的体外侵袭和迁移。
Oncol Lett. 2012 Nov;4(5):1125-1129. doi: 10.3892/ol.2012.863. Epub 2012 Aug 16.
5
Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.随机对照试验研究间隔压缩化疗治疗局限性尤因肉瘤:儿童肿瘤协作组的报告。
J Clin Oncol. 2012 Nov 20;30(33):4148-54. doi: 10.1200/JCO.2011.41.5703. Epub 2012 Oct 22.
6
Wnt5a promotes ewing sarcoma cell migration through upregulating CXCR4 expression.Wnt5a 通过上调 CXCR4 表达促进尤文肉瘤细胞迁移。
BMC Cancer. 2012 Oct 18;12:480. doi: 10.1186/1471-2407-12-480.
7
IL-6 promotes ICAM-1 expression and cell motility in human osteosarcoma.IL-6 促进人骨肉瘤中细胞间黏附分子-1 的表达和细胞迁移。
Cancer Lett. 2013 Jan 1;328(1):135-43. doi: 10.1016/j.canlet.2012.08.029. Epub 2012 Aug 29.
8
Expression of Vascular Endothelial Growth Factor correlates with the advance of clinical osteosarcoma.血管内皮生长因子的表达与临床骨肉瘤的进展相关。
Int Orthop. 2012 Nov;36(11):2307-13. doi: 10.1007/s00264-012-1629-z. Epub 2012 Aug 2.
9
EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.EWS/FLI1 通过调节 miRNA-708 调控 Ewing 肉瘤中的 EYA3,导致细胞存活和化疗耐药性增加。
Mol Cancer Res. 2012 Aug;10(8):1098-108. doi: 10.1158/1541-7786.MCR-12-0086. Epub 2012 Jun 20.
10
Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12.小分子 STAT3 抑制剂 LLL12 的抗血管生成活性。
PLoS One. 2012;7(4):e35513. doi: 10.1371/journal.pone.0035513. Epub 2012 Apr 17.